Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neurofibrosarcoma 1Colorectal Neoplasms 1

Interventions

Doxorubicin 3pazopanib 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Ifosfamide 2sapanisertib 1romidepsin 1pegfilgrastim 1metarrestin 1cixutumumab 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiation 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Ipilimumab 1HhAntag691 1Filgrastim 1Etoposide 1Diathermy 1CTLA-4 Antigen 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neurofibrosarcoma × metarrestin × Clear all
NCT04222413 2026-04-24

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
116 enrolled
GastrointestinalSarcoma

Pancreatic Neoplasms, Colorectal Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡